NEXGEL (NXGL) is trading down at $0.17 (-2.30%), as of the latest quote. It operates in the Health Care sector.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.21M | $717.0K | $674.0K | $1.55M | $2.05M | $4.09M | $8.69M | $11.4M |
| Growth (year over year) | — | −67.6% | −6.0% | +130.1% | +32.0% | +99.7% | +112.5% | +31.5% |
| Gross profit | $514.0K | −$137.0K | −$291.0K | $8.00K | $256.0K | $374.0K | $2.75M | $4.51M |
| Gross margin | 23.2% | −19.1% | −43.2% | 0.5% | 12.5% | 9.1% | 31.6% | 39.5% |
| Operating income | −$1.89M | −$1.92M | −$2.26M | −$2.57M | −$3.35M | −$3.48M | −$3.55M | −$3.35M |
| Operating margin | −85.3% | −268.3% | −335.3% | −165.7% | −163.5% | −85.0% | −40.9% | −29.3% |
| Net income | −$1.89M | −$1.92M | −$2.26M | −$4.31M | −$4.75M | −$3.16M | −$3.28M | −$3.00M |
| Net margin | −85.3% | −268.2% | −335.9% | −277.9% | −231.7% | −77.2% | −37.8% | −26.3% |
| EPS (diluted) | −$0.38 | −$0.14 | −$1.05 | −$1.45 | −$0.85 | −$0.56 | −$0.50 | −$0.38 |
| Balance sheet | ||||||||
| Cash and equivalents | $0 | $261.0K | $32.0K | $13.3M | $1.10M | $2.70M | $1.81M | $317.0K |
| Total assets | $739.0K | $1.89M | $2.26M | $17.0M | $10.4M | $9.96M | $11.0M | $10.5M |
| Total liabilities | $458.0K | $1.51M | $2.19M | $4.90M | $2.72M | $4.79M | $4.90M | $5.57M |
| Long-term debt | — | — | — | — | $283.0K | $593.0K | $685.0K | $588.0K |
| Shareholders' equity | $281.0K | $380.0K | $71.0K | $12.1M | $7.64M | $4.70M | $5.75M | $4.46M |
| Cash flow | ||||||||
| Operating cash flow | −$1.54M | −$1.81M | −$1.80M | −$2.75M | −$2.99M | −$3.24M | −$3.87M | −$1.31M |
| Capital expenditure | — | $0 | $312.0K | $269.0K | $96.0K | $696.0K | $443.0K | $68.0K |
| Free cash flow | — | −$1.81M | −$2.11M | −$3.02M | −$3.09M | −$3.93M | −$4.31M | −$1.38M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.94M | $3.04M | $2.81M | $2.88M | $2.93M | $2.80M | $2.65M | $3.69M |
| Growth (year over year) | +140.8% | +181.4% | +121.6% | +100.3% | −0.2% | −8.1% | −5.6% | +27.8% |
| Gross profit | $1.16M | $1.14M | $1.19M | $1.26M | $1.24M | $820.0K | $1.06M | $1.11M |
| Gross margin | 39.3% | 37.5% | 42.3% | 43.6% | 42.4% | 29.3% | 40.0% | 30.1% |
| Operating income | −$788.0K | −$841.0K | −$777.0K | −$636.0K | −$725.0K | −$1.21M | −$958.0K | −$2.50M |
| Operating margin | −26.8% | −27.6% | −27.7% | −22.1% | −24.7% | −43.4% | −36.2% | −68.0% |
| Net income | −$693.0K | −$850.0K | −$712.0K | −$665.0K | −$653.0K | −$970.0K | −$927.0K | −$3.63M |
| Net margin | −23.6% | −27.9% | −25.4% | −23.1% | −22.3% | −34.7% | −35.0% | −98.6% |
| EPS (diluted) | −$0.11 | −$0.11 | −$0.09 | −$0.09 | −$0.08 | −$0.12 | −$0.11 | −$0.40 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.06M | $1.81M | $1.19M | $725.0K | $938.0K | $317.0K | $2.12M | $1.71M |
| Total assets | $10.6M | $11.0M | $10.4M | $9.71M | $11.6M | $10.5M | $11.6M | $26.4M |
| Total liabilities | $5.59M | $4.90M | $4.87M | $4.66M | $6.04M | $5.57M | $7.12M | $21.0M |
| Long-term debt | $709.0K | $685.0K | $662.0K | $638.0K | $614.0K | $588.0K | $563.0K | — |
| Shareholders' equity | $4.69M | $5.75M | $5.21M | $4.67M | $5.19M | $4.46M | $3.99M | $4.95M |
| Cash flow | ||||||||
| Operating cash flow | −$1.22M | −$859.0K | −$400.0K | −$407.0K | −$785.0K | $281.0K | −$504.0K | −$2.20M |
| Capital expenditure | $13.0K | $69.0K | — | — | $8.00K | $40.0K | $9.00K | — |
| Free cash flow | −$1.23M | −$928.0K | — | — | −$793.0K | $241.0K | −$513.0K | — |
From NEXGEL's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning NEXGEL in our feed yet.